The State of Texas Top Legal Officer Files Lawsuit Against Tylenol Producers Concerning Autism Allegations

Judicial Proceedings
The Texas Attorney General, who supports former President Trump who is running for the United States Senate, claimed the drug companies of hiding the risks of acetaminophen

The top legal official in Texas Ken Paxton is suing the producers of Tylenol, claiming the corporations hid potential risks that the drug posed to children's brain development.

The court filing arrives four weeks after Donald Trump publicized an unsubstantiated connection between consuming Tylenol - referred to as acetaminophen - throughout gestation and autism spectrum disorder in children.

Paxton is suing J&J, which previously sold the medication, the only pain reliever suggested for pregnant women, and Kenvue, which now manufacturers it.

In a official comment, he stated they "deceived the public by gaining financially from suffering and pushing pills ignoring the potential hazards."

The manufacturer states there is insufficient reliable data connecting Tylenol to autism spectrum disorder.

"These companies lied for decades, knowingly endangering numerous people to line their pockets," the attorney general, a Republican, stated.

The company stated officially that it was "seriously troubled by the dissemination of inaccurate information on the safety of paracetamol and the possible consequences that could have on the health of women and children in America."

On its official site, Kenvue also said it had "regularly reviewed the relevant science and there is lacking reliable evidence that indicates a proven link between consuming acetaminophen and autism."

Associations representing medical professionals and health professionals concur.

ACOG has stated paracetamol - the key substance in acetaminophen - is one of the few options for pregnant women to treat discomfort and fever, which can present serious health risks if ignored.

"In multiple decades of research on the utilization of paracetamol in gestation, not a single reputable study has conclusively proven that the usage of acetaminophen in any period of pregnancy leads to neurodevelopmental disorders in children," the organization commented.

This legal action cites recent announcements from the Trump administration in arguing the drug is potentially dangerous.

Last month, the former president raised alarms from health experts when he told pregnant women to "struggle intensely" not to consume acetaminophen when ill.

The FDA then released a statement that medical professionals should think about restricting the usage of acetaminophen, while also stating that "a proven link" between the drug and autism spectrum disorder in minors has remains unverified.

The Health Department head RFK Jr, who supervises the Food and Drug Administration, had pledged in spring to initiate "comprehensive study program" that would establish the cause of autism spectrum disorder in a short period.

But specialists advised that finding a unique factor of autism - believed by scientists to be the outcome of a complicated interplay of inherited and surrounding conditions - would not be simple.

Autism is a type of enduring cognitive variation and condition that impacts how individuals perceive and interact with the surroundings, and is recognized using doctors' observations.

In his court filing, Paxton - who supports Trump who is campaigning for US Senate - claims Kenvue and Johnson & Johnson "willfully ignored and attempted to silence the evidence" around paracetamol and autism.

The lawsuit seeks to make the firms "eliminate any commercial messaging" that states acetaminophen is safe for expectant mothers.

The court case mirrors the complaints of a group of parents of minors with autism and attention deficit hyperactivity disorder who sued the producers of acetaminophen in two years ago.

The court dismissed the case, saying research from the plaintiffs' authorities was not conclusive.

Jennifer Jackson
Jennifer Jackson

A seasoned business analyst with over a decade of experience in tech and finance, passionate about data-driven insights and innovation.